These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28012835)

  • 1. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.
    Boncelj Svetek M; Eržen B; Kanc K; Šabovič M
    J Diabetes Complications; 2017 Mar; 31(3):544-550. PubMed ID: 28012835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
    Lunder M; Janić M; Jug B; Sabovič M
    Eur J Intern Med; 2012 Apr; 23(3):261-6. PubMed ID: 22385885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study.
    Turk Veselič M; Žorž N; Eržen B; Škerl P; Novaković S; Janić M; Šabovič M
    Int Angiol; 2018 Oct; 37(5):356-364. PubMed ID: 29952159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients.
    Savić V; Eržen B; Janić M; Lunder M; Boncelj M; Kanc K; Janež A; Šabović M
    Diab Vasc Dis Res; 2013 Sep; 10(5):420-5. PubMed ID: 23811602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Arterial Wall Characteristics in Patients After Myocardial Infarction with a Very Low Dose of Fluvastatin and Valsartan: A Proof-of-Concept Study.
    Turk Veselič M; Eržen B; Hanžel J; Piletič Ž; Šabovič M
    Med Sci Monit; 2018 Sep; 24():6892-6899. PubMed ID: 30266894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of age-associated arterial wall changes by low-dose valsartan.
    Lunder M; Janic M; Sabovic M
    Eur J Prev Cardiol; 2012 Dec; 19(6):1243-9. PubMed ID: 21933833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus.
    Lunder M; Janić M; Savić V; Janež A; Kanc K; Šabovič M
    Diabetes Res Clin Pract; 2017 May; 127():181-186. PubMed ID: 28384560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation.
    Hausberg M; Kosch M; Stam F; Heidenreich S; Kisters K; Rahn KH; Barenbrock M
    Kidney Int; 2001 Apr; 59(4):1473-9. PubMed ID: 11260410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
    Lunder M; Janić M; Japelj M; Juretič A; Janež A; Šabovič M
    Cardiovasc Diabetol; 2018 Dec; 17(1):153. PubMed ID: 30509271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study.
    Lunder M; Janić M; Habjan S; Sabovič M
    Atherosclerosis; 2011 Apr; 215(2):446-51. PubMed ID: 21300350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease].
    Soboleva GN; Pogorelova OA; Kuznetsova TV; Masenko VP; Fomicheva OA; Chernova NA; Rogoza AN; Balakhonova TV; Karpov IuA
    Kardiologiia; 2007; 47(11):9-13. PubMed ID: 18260957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
    Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M
    Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
    Karalliedde J; Smith A; DeAngelis L; Mirenda V; Kandra A; Botha J; Ferber P; Viberti G
    Hypertension; 2008 Jun; 51(6):1617-23. PubMed ID: 18426991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction.
    Westphal S; Abletshauser C; Luley C
    Coron Artery Dis; 2009 Jan; 20(1):81-5. PubMed ID: 19060628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
    Janić M; Lunder M; France Štiglic A; Jerin A; Skitek M; Černe D; Marc J; Drevenšek G; Šabovič M
    Vascul Pharmacol; 2017 Dec; 99():45-52. PubMed ID: 28951255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term improvement of arterial wall characteristics in patients with diabetes mellitus type 1 using cyclic, intermittent treatment with a low-dose fluvastatin and valsartan combination.
    Savić V; Janić M; Lunder M; Kanc K; Janež A; Eržen B; Šabovič M
    Exp Ther Med; 2015 Sep; 10(3):1207-1211. PubMed ID: 26622466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
    Koh KK; Lim S; Choi H; Lee Y; Han SH; Lee K; Oh PC; Sakuma I; Shin EK; Quon MJ
    Diabetes; 2013 Oct; 62(10):3547-52. PubMed ID: 23863812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tauroursodeoxycholic Acid Reduces Arterial Stiffness and Improves Endothelial Dysfunction in Type 2 Diabetic Mice.
    Battson ML; Lee DM; Jarrell DK; Hou S; Ecton KE; Phan AB; Gentile CL
    J Vasc Res; 2017; 54(5):280-287. PubMed ID: 28930750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Qi WW; Liu T; Xu G; Li LF; Liang YZ; Ye L; Li GP
    Trials; 2015 Aug; 16():336. PubMed ID: 26248619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis.
    Han SH; Kang EW; Yoon SJ; Yoon HS; Lee HC; Yoo TH; Choi KH; Han DS; Kang SW
    Nephrol Dial Transplant; 2011 Nov; 26(11):3722-8. PubMed ID: 21385862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.